Singapore
BioHelix
Node
Our APAC wet lab base of operations — anchored in Biopolis, powered by MiRXES's Industry 4.0 IVD infrastructure, and bridging India's multiomics intelligence to Asia-Pacific's most advanced autonomous manufacturing ecosystem.
Why Singapore is the Right APAC Node
India gives us data richness, cost arbitrage, and the world's most diverse genomic population. Singapore gives us regulatory credibility, advanced manufacturing infrastructure, APAC market access, and the IP protection framework that global pharma partners require before committing to co-development deals. The two nodes are strategically complementary — not competitive.
The Core Logic
India is where we generate insights — the multiomics data, the AI models, the hypothesis engine. Singapore is where we execute and validate — the i4.0 wet lab, the regulatory dossier, the APAC commercial bridge. Together, they form a closed-loop discovery-to-validation corridor that neither geography alone can offer.
MiRXES — The i4.0 Wet Lab Foundation
MiRXES is not just a potential wet lab partner — it is the most strategically aligned company in Singapore for our thesis. As an A*STAR spinoff building miRNA-powered multi-cancer early detection with Southeast Asia's most advanced Industry 4.0 IVD manufacturing facility, MiRXES sits at the exact intersection of our multiomics + autonomous lab + APAC market strategy. The partnership is a strategic fit at every dimension.
MiRXES Pte Ltd — Anchor Lab Partner
A*STAR spinoff · Singapore · Founded 2014 · USD $130M raised · HKEX IPO filed · FDA Breakthrough Device Designation
JTC MedTech Hub
3× capacity scalable
Project CADENCE
MiRXES diagnostics
Series D + HKEX IPO
NUS / NUH co-development
What Makes MiRXES's i4.0 Facility Unique
- Plug-and-play system: accommodates new technologies across prototyping, validation, and manufacturing without facility redesign
- "Any mix, any volume" principle: seamless connections across automation, extraction, and automated analysis — exactly the FAL philosophy we need
- Parallel production lines: up to 5 simultaneous product lines, tripling throughput within each product category
- Digitalization backbone: tracks quality across all product lines, examines efficiencies, proposes improvements — built-in closed-loop optimization
- A*STAR ARTC MoU: joint R&D on automation, digitalization, disruption analysis, and sustainability for IVD and research-use-only applications
- Reconfigurable joint lab (2024): new A*STAR–MiRXES joint lab for scalable, reconfigurable IVD manufacturing — directly aligned with LabOS integration
- ID3EAL platform: miRNA discovery tools and services already licensed to global biopharma — our multiomics layer adds genomic and proteomic dimensions
- J&J partnership established: global pharma already validated as a partner — provides commercial co-sell template
MiRXES brings i4.0 execution infrastructure + miRNA platform + APAC regulatory approvals + J&J-validated commercial model. We bring India multiomics data + OmicsOS AI + LabOS orchestration + India market entry. Neither of us has what the other has. This is a genuine strategic complement, not a vendor relationship.
The India–Singapore Discovery Corridor
The BioHelix Node creates a bi-directional discovery corridor. Computational work runs in India (lower cost, larger talent pool). Wet lab validation runs in Singapore via MiRXES's i4.0 infrastructure (regulatory-grade, globally credible). Data flows both ways through LabOS, with OmicsOS continuously learning from every experimental cycle.
India Node · OmicsOS Engine
Multiomics AI computation
India Biomarker Atlas
Hypothesis generation
Protocol design (NLP)
CDSCO regulatory intelligence
Singapore Node · BioHelix Wet Lab
MiRXES i4.0 execution
miRNA + IVD manufacturing
A*STAR validation pipelines
Structured data return
HSA + FDA-bridging dossiers
Workflow: A Discovery Sprint on the Corridor
Hypothesis (India) — OmicsOS
Customer submits disease area + target class. OmicsOS runs multiomics integration across India cohort data, scRNA-seq, and published literature to generate ranked target list with confidence scores and biomarker candidates.
Protocol Design (India/Remote) — LabOS AI agent
NLP-driven protocol specification. LabOS checks MiRXES facility inventory, instrument availability, and estimated turnaround via the API integration with their i4.0 scheduling system. Quote generated within hours.
Execution (Singapore) — MiRXES i4.0 + BioHelix Scientists
Robotic liquid handling, automated extraction, miRNA profiling, qPCR / next-gen sequencing. "Any mix, any volume" principle allows concurrent execution of multiple experimental arms. All data logged to LabOS in real time.
Analysis + Insight (India) — OmicsOS closed loop
Structured experimental data returned to OmicsOS. Models update. Next experimental cycle designed. Results packaged for customer as a validated insight report with confidence intervals, reproducibility scores, and recommended next steps.
Regulatory Package (Singapore) — ClinicalBridge
For programs requiring regulatory-grade output: HSA (Singapore) dossier first. Then FDA/EMA bridging via MiRXES's existing Breakthrough Device experience. CDSCO India dossier generated in parallel for domestic programs.
Singapore as the Regulatory Bridge
Singapore's Health Sciences Authority (HSA) is one of the most progressive regulatory agencies in Asia and is recognized as a reference agency by ASEAN member states. HSA approval creates a direct pathway for ASEAN market access, and Singapore's existing bilateral recognition agreements with the EU and US create a validated stepping-stone for global filings.
Domestic approval
New Drugs Rules 2019
ASEAN reference agency
Breakthrough pathway
APAC bridging study
via Singapore data
Fast-track for APAC
validated assets
MiRXES FDA BDD
experience used
MiRXES holds FDA Breakthrough Device Designation (BDD) for GASTROClear — providing a validated regulatory navigation template for our co-developed programs.
MiRXES Partnership Tier Structure
The relationship with MiRXES should evolve across three tiers, starting with a services arrangement and progressing toward co-IP and joint ventures as the relationship deepens and mutual value is demonstrated.
| Tier | Model | What We Access | What MiRXES Gets | Timeline |
|---|---|---|---|---|
| Tier 1 | Lab Services / CRO | i4.0 facility access, instrument time, scientist hours, data return via LabOS API | Revenue from lab services, our AI-driven experimental efficiency increases their throughput | Months 1–12 |
| Tier 2 | Technology Partnership | ID3EAL platform integration into OmicsCloud, joint protocol development, MiRXES brand on our Singapore offerings | OmicsOS multiomics capability added to ID3EAL, India market entry via our network, co-branded APAC positioning | Months 6–24 |
| Tier 3 | Co-IP / Joint Venture | Shared IP on India-validated + Singapore-executed biomarker panels, joint regulatory dossiers, co-commercialization | Equity in India biomarker programs, revenue share on APAC sales of jointly developed diagnostics, BioHelix-branded venture | Year 2–3+ |
| Tier 4 | BioHelix Singapore JV | Shared Singapore legal entity, combined Singapore ecosystem access, joint APAC growth narrative | India commercialization of GASTROClear-class products via Apollo/hospital network, shared APAC discovery platform | Year 3–5 |
The India Angle — A Known Strategic Priority for MiRXES
MiRXES has explicitly stated its ambition to expand across Southeast Asia (Thailand, Malaysia, Indonesia via the EnterpriseSG Scale-up SG programme) — but India is conspicuously absent from their current expansion map. With 1.4 billion people, the world's highest gastric cancer burden in certain populations, and Apollo's 10,000+ bed hospital network, India is MiRXES's biggest untapped market — and we are the only team positioned to unlock it for them.
Full Singapore Ecosystem Leverage
NSG BioLabs @ Biopolis
35,000 sq ft of BSL-2 certified co-working wet labs across 3 sites. Flexible "plug-and-play" operational from day one. Partnered with Merck, Temasek's ClavystBio, and Amgen. Our Singapore team office base before dedicated space.
A*STAR DxD Hub
Diagnostics Development Hub — Singapore's national platform for translating diagnostics from research to commercial readiness. Co-funded multiple MiRXES programs. Access pathway for our biomarker panels.
Genome Institute of Singapore
A*STAR institute at Biopolis. SEAGOS (SEA Genomics) datasets. Singapore Chinese, Malay, and Indian population genomics. Complements our India cohort data — combined India + SEA reference genome capability.
SGInnovate + EDBI
Government deep-tech innovation programs. SGInnovate supports deep-tech venture building; EDBI (EDB's investment arm) backs Singapore-based biotech. Both reinforce the depth of the Singapore life-sciences ecosystem.
Flagship Pioneering MoU
Flagship (creator of Moderna) signed a S$100M co-investment MoU with A*STAR for Singapore biotech. Direct access to Flagship Pioneering's venture creation model — the global gold standard for biotech studio building.
APAC Pharma HQ Access
Pfizer, Novartis, AZ, Roche, J&J, Sanofi, Takeda — all have Singapore APAC HQs. BD conversations happen in Singapore. Our BioHelix Node puts us in the same room as the APAC heads of R&D partnerships at all major pharma.
BioHelix Node Phased Build
Year 1 — Establish & Anchor
- Register Singapore entity (Pte Ltd) — 1 week
- Desk space at NSG BioLabs, Biopolis (flexible, immediate)
- Sign Tier 1 lab services MoU with MiRXES
- LabOS API integration with MiRXES scheduling system
- Apply for SGInnovate co-investment grant
- Target: 2 Discovery Sprint programs executed through MiRXES facility
- Attend BioAsia, Biopolis networking events
Year 2–3 — Deepen & Co-Develop
- Tier 2 Technology Partnership MoU with MiRXES (ID3EAL + OmicsCloud integration)
- Dedicated Singapore R&D scientist hire (2–3 FTEs)
- Apply for A*STAR Industry Alignment Fund (IAF-ICP)
- First joint biomarker panel (India cancer signature validated in Singapore)
- Explore SEA population genomics collaboration with GIS
Singapore Node Team
| Role | Hire Timeline | Profile | Why Singapore-Based |
|---|---|---|---|
| Head of Singapore Operations | Month 3–6 | Ex-A*STAR / MNC pharma. Regulatory + BD background. Singapore PR or citizen. | Local BD relationships, HSA regulatory navigation, MiRXES liaison |
| Molecular Biologist / Lab Scientist | Month 6–9 | PhD, NGS/miRNA experience. Biopolis background preferred. | On-site at MiRXES facility to oversee experimental execution quality |
| Regulatory Affairs Specialist | Month 9–12 | HSA submission experience, ASEAN harmonization knowledge, IVD background. | Singapore is the regulatory dossier hub for all APAC programs |
Why the Singapore Corridor Matters
Not a Single-Country Bet
We have operational access to Southeast Asia's most advanced Industry 4.0 IVD manufacturing facility as our wet lab partner. We sit within the Biopolis ecosystem — the same hub that houses Pfizer, Novartis, AZ, Roche, and 40+ global pharma R&D operations. Our Singapore entity provides IP protection and APAC regulatory credibility that an India-only company cannot offer. The India–Singapore corridor is our structural competitive moat.
De-risks India-Only Perception
Global pharma partners often hesitate at India-only biotech. Singapore as the execution and regulatory node signals global ambition, credible IP protection (strong SG IP law), and APAC commercial readiness.